TAZ and RUNX2 awareness in pulmonary hypertension due to left heart disease

Vinicio A de Jesus Perez¹, Yen-Chun Lai^{2

3}

Affiliations

¹ Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford School of Medicine, Palo Alto, CA, USA.
² Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN, USA yelai@iu.edu.
³ Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.

Editorial

Vinicio A de Jesus Perez et al. Eur Respir J. 2024.

. 2024 Nov 14;64(5):2400905.

doi: 10.1183/13993003.00905-2024. Print 2024 Nov.

Vinicio A de Jesus Perez¹, Yen-Chun Lai^{2

3}

¹ Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford School of Medicine, Palo Alto, CA, USA.
² Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN, USA yelai@iu.edu.
³ Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.

No abstract available

Conflict of interest statement

Conflict of interest: The authors report no conflict of interest.

RUNX2 is stabilised by TAZ and drives pulmonary artery calcification and lung vascular remodelling in pulmonary hypertension due to left heart disease.
Liu SF, Kucherenko MM, Sang P, Li Q, Yao J, Nambiar Veetil N, Gransar T, Alesutan I, Voelkl J, Salinas G, Grune J, Simmons S, Knosalla C, Kuebler WM. Liu SF, et al. Eur Respir J. 2024 Nov 14;64(5):2300844. doi: 10.1183/13993003.00844-2023. Print 2024 Nov. Eur Respir J. 2024. PMID: 39542509